ECOVYST INC (ECVT)

US27923Q1094 - Common Stock

7.54  -0.04 (-0.53%)

After market: 7.54 0 (0%)

Fundamental Rating

4

ECVT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 85 industry peers in the Chemicals industry. ECVT has an average financial health and profitability rating. ECVT is valued correctly, but it does not seem to be growing.



6

1. Profitability

1.1 Basic Checks

In the past year ECVT was profitable.
ECVT had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ECVT reported negative net income in multiple years.
Each year in the past 5 years ECVT had a positive operating cash flow.

1.2 Ratios

With a Return On Assets value of 2.92%, ECVT perfoms like the industry average, outperforming 56.63% of the companies in the same industry.
ECVT's Return On Equity of 7.36% is in line compared to the rest of the industry. ECVT outperforms 57.83% of its industry peers.
ECVT has a Return On Invested Capital (4.61%) which is comparable to the rest of the industry.
ECVT had an Average Return On Invested Capital over the past 3 years of 4.57%. This is below the industry average of 6.59%.
The last Return On Invested Capital (4.61%) for ECVT is above the 3 year average (4.57%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.92%
ROE 7.36%
ROIC 4.61%
ROA(3y)0.18%
ROA(5y)-1.27%
ROE(3y)0.54%
ROE(5y)-3.15%
ROIC(3y)4.57%
ROIC(5y)3.35%

1.3 Margins

ECVT has a better Profit Margin (7.72%) than 75.90% of its industry peers.
ECVT's Profit Margin has improved in the last couple of years.
ECVT's Operating Margin of 14.27% is fine compared to the rest of the industry. ECVT outperforms 78.31% of its industry peers.
In the last couple of years the Operating Margin of ECVT has grown nicely.
The Gross Margin of ECVT (28.03%) is comparable to the rest of the industry.
ECVT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 14.27%
PM (TTM) 7.72%
GM 28.03%
OM growth 3Y8.79%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5Y16.76%
GM growth 3Y-2.02%
GM growth 5Y3.02%

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ECVT is destroying value.
ECVT has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ECVT has been reduced compared to 5 years ago.
Compared to 1 year ago, ECVT has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.03, we must say that ECVT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.03, ECVT is not doing good in the industry: 77.11% of the companies in the same industry are doing better.
The Debt to FCF ratio of ECVT is 8.05, which is on the high side as it means it would take ECVT, 8.05 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 8.05, ECVT is in line with its industry, outperforming 56.63% of the companies in the same industry.
A Debt/Equity ratio of 1.17 is on the high side and indicates that ECVT has dependencies on debt financing.
With a Debt to Equity ratio value of 1.17, ECVT is not doing good in the industry: 73.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 8.05
Altman-Z 1.03
ROIC/WACC0.59
WACC7.87%

2.3 Liquidity

ECVT has a Current Ratio of 2.54. This indicates that ECVT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.54, ECVT is in the better half of the industry, outperforming 65.06% of the companies in the same industry.
ECVT has a Quick Ratio of 2.06. This indicates that ECVT is financially healthy and has no problem in meeting its short term obligations.
ECVT has a better Quick ratio (2.06) than 78.31% of its industry peers.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.06

3

3. Growth

3.1 Past

The earnings per share for ECVT have decreased strongly by -34.18% in the last year.
Measured over the past years, ECVT shows a decrease in Earnings Per Share. The EPS has been decreasing by -2.67% on average per year.
The Revenue has decreased by -0.81% in the past year.
The Revenue for ECVT have been decreasing by -10.87% on average. This is quite bad
EPS 1Y (TTM)-34.18%
EPS 3Y-13.88%
EPS 5Y-2.67%
EPS Q2Q%-26.32%
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y11.7%
Revenue growth 5Y-10.87%
Sales Q2Q%3.4%

3.2 Future

The Earnings Per Share is expected to grow by 13.36% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.70% on average over the next years.
EPS Next Y-27.32%
EPS Next 2Y5.79%
EPS Next 3Y13.36%
EPS Next 5YN/A
Revenue Next Year4.02%
Revenue Next 2Y4.49%
Revenue Next 3Y4.7%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 14.50, the valuation of ECVT can be described as correct.
ECVT's Price/Earnings ratio is a bit cheaper when compared to the industry. ECVT is cheaper than 74.70% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.28. ECVT is valued slightly cheaper when compared to this.
ECVT is valuated reasonably with a Price/Forward Earnings ratio of 8.86.
ECVT's Price/Forward Earnings ratio is rather cheap when compared to the industry. ECVT is cheaper than 87.95% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ECVT to the average of the S&P500 Index (23.53), we can say ECVT is valued rather cheaply.
Industry RankSector Rank
PE 14.5
Fwd PE 8.86

4.2 Price Multiples

ECVT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ECVT is cheaper than 72.29% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ECVT is valued cheaper than 89.16% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.2
EV/EBITDA 8.6

4.3 Compensation for Growth

The decent profitability rating of ECVT may justify a higher PE ratio.
ECVT's earnings are expected to grow with 13.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.79%
EPS Next 3Y13.36%

0

5. Dividend

5.1 Amount

ECVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ECOVYST INC

NYSE:ECVT (1/14/2025, 8:04:00 PM)

After market: 7.54 0 (0%)

7.54

-0.04 (-0.53%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)N/A N/A
Inst Owners97.16%
Inst Owner Change0.23%
Ins Owners1.18%
Ins Owner Change-0.22%
Market Cap878.49M
Analysts84.62
Price Target10.35 (37.27%)
Short Float %2.91%
Short Ratio3.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.83%
Min EPS beat(2)-17.17%
Max EPS beat(2)-10.49%
EPS beat(4)0
Avg EPS beat(4)-13.47%
Min EPS beat(4)-19.03%
Max EPS beat(4)-7.2%
EPS beat(8)3
Avg EPS beat(8)-5.05%
EPS beat(12)6
Avg EPS beat(12)-0.79%
EPS beat(16)10
Avg EPS beat(16)147.23%
Revenue beat(2)0
Avg Revenue beat(2)-5.55%
Min Revenue beat(2)-5.57%
Max Revenue beat(2)-5.54%
Revenue beat(4)0
Avg Revenue beat(4)-3.96%
Min Revenue beat(4)-5.57%
Max Revenue beat(4)-0.04%
Revenue beat(8)0
Avg Revenue beat(8)-4.75%
Revenue beat(12)4
Avg Revenue beat(12)-1.64%
Revenue beat(16)7
Avg Revenue beat(16)-3.76%
PT rev (1m)4.41%
PT rev (3m)-0.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.73%
Valuation
Industry RankSector Rank
PE 14.5
Fwd PE 8.86
P/S 1.26
P/FCF 8.2
P/OCF 5.15
P/B 1.2
P/tB 4.05
EV/EBITDA 8.6
EPS(TTM)0.52
EY6.9%
EPS(NY)0.85
Fwd EY11.28%
FCF(TTM)0.92
FCFY12.2%
OCF(TTM)1.46
OCFY19.42%
SpS5.97
BVpS6.26
TBVpS1.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.92%
ROE 7.36%
ROCE 5.74%
ROIC 4.61%
ROICexc 4.96%
ROICexgc 7.29%
OM 14.27%
PM (TTM) 7.72%
GM 28.03%
FCFM 15.41%
ROA(3y)0.18%
ROA(5y)-1.27%
ROE(3y)0.54%
ROE(5y)-3.15%
ROIC(3y)4.57%
ROIC(5y)3.35%
ROICexc(3y)4.87%
ROICexc(5y)3.55%
ROICexgc(3y)7.22%
ROICexgc(5y)5.21%
ROCE(3y)5.69%
ROCE(5y)4.17%
ROICexcg growth 3Y56.14%
ROICexcg growth 5Y6.02%
ROICexc growth 3Y46.93%
ROICexc growth 5Y12.49%
OM growth 3Y8.79%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5Y16.76%
GM growth 3Y-2.02%
GM growth 5Y3.02%
F-Score6
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 8.05
Debt/EBITDA 4.54
Cap/Depr 71.32%
Cap/Sales 9.13%
Interest Coverage 1.96
Cash Conversion 90.65%
Profit Quality 199.52%
Current Ratio 2.54
Quick Ratio 2.06
Altman-Z 1.03
F-Score6
WACC7.87%
ROIC/WACC0.59
Cap/Depr(3y)75.63%
Cap/Depr(5y)72.19%
Cap/Sales(3y)8.82%
Cap/Sales(5y)14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.18%
EPS 3Y-13.88%
EPS 5Y-2.67%
EPS Q2Q%-26.32%
EPS Next Y-27.32%
EPS Next 2Y5.79%
EPS Next 3Y13.36%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y11.7%
Revenue growth 5Y-10.87%
Sales Q2Q%3.4%
Revenue Next Year4.02%
Revenue Next 2Y4.49%
Revenue Next 3Y4.7%
Revenue Next 5YN/A
EBIT growth 1Y-11.5%
EBIT growth 3Y21.51%
EBIT growth 5Y-6.06%
EBIT Next Year42.48%
EBIT Next 3Y19.51%
EBIT Next 5YN/A
FCF growth 1Y7.78%
FCF growth 3Y-17.03%
FCF growth 5Y-9.17%
OCF growth 1Y10.56%
OCF growth 3Y-14.94%
OCF growth 5Y-11.16%